Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 257 matching trials from the live ClinicalTrials.gov search.
Filters: "early Parkinson" Clear all
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

NCT02807675
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, LIP, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 3 Interventional

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

NCT00036218
View directory record Official record
Conditions
Parkinson Disease
Interventions
sumanirole, ropinirole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
93
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Carmichael, California + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2006 · Synced Oct 10, 2026, 4:27 PM EDT
Terminated No phase listed Observational

The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)

NCT00804479
View directory record Official record
Conditions
Parkinson's Disease
Interventions
No intervention.
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 1Phase 2 Interventional

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

NCT05083260
View directory record Official record
Conditions
Parkinson Disease
Interventions
NE3107, placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
16
States / cities
Englewood, Colorado • Boca Raton, Florida • Hallandale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 10, 2026, 4:27 PM EDT
Recruiting No phase listed Observational

Natural History Study of Synucleinopathies

NCT01799915
View directory record Official record
Conditions
Patients With Synucleinopathies, Neurogenic Orthostatic Hypotension, Pure Autonomic Failure, REM Sleep Behavior Disorder, Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Shy-Drager Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

NCT00099268
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 70 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 10, 2026, 4:27 PM EDT
Not listed Not applicable Interventional

Timing of Acute Palliative Care Consultation in Critically Ill Patients

NCT02858778
View directory record Official record
Conditions
Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5, Hepatic Encephalopathy, Sepsis, Dementia, Multiple Sclerosis, Parkinson's Disease, In-Hospital Cardiac Arrest, Solid Organ Cancer
Interventions
Early order of palliative care consultation
Other
Lead sponsor
Wayne State University
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 10, 2026, 4:27 PM EDT
Completed No phase listed Observational

The GBA Multimodal Study in Parkinson's Disease

NCT04101968
View directory record Official record
Conditions
Parkinson Disease, GBA Gene Mutation, Gaucher Disease
Interventions
PET scan, neuroQWERTY
Diagnostic Test
Lead sponsor
Pacific Parkinson's Research Centre
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

NCT03329508
View directory record Official record
Conditions
Parkinson Disease, Early Parkinson's Disease
Interventions
P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
45
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 10, 2026, 4:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Personal KinetiGraph® Clinical Validation Study

NCT05251701
View directory record Official record
Conditions
Movement Disorders, Parkinson Disease
Interventions
Personal KinetiGraph® (PKG®) System
Device
Lead sponsor
Global Kinetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families

NCT00273351
View directory record Official record
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
[123I]B-CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT04332653
View directory record Official record
Conditions
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer
Interventions
NT-I7, pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Tampa, Florida • Detroit, Michigan • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Rasagiline on Cognition in Parkinson's Disease

NCT01382342
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

NCT04658186
View directory record Official record
Conditions
Early-stage Parkinson's Disease
Interventions
UCB0599, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
40 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Not applicable Interventional

Emotional Prosody Treatment in Parkinson's

NCT01956266
View directory record Official record
Conditions
Parkinson Disease
Interventions
Emotional prosodic treatment
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Study of Urate Elevation in Parkinson's Disease, Phase 3

NCT02642393
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Inosine, Placebo
Drug
Lead sponsor
Michael Alan Schwarzschild
Other
Eligibility
30 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 10, 2026, 4:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Repurposing Lithium for Parkinson's Disease: a RCT

NCT06339034
View directory record Official record
Conditions
Parkinson Disease
Interventions
Lithium, Placebo
Dietary Supplement · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 10, 2026, 4:27 PM EDT
Not yet recruiting Phase 1 Interventional

AAV2-hAADC for Parkinson's Disease (PDCS-01)

NCT07267065
View directory record Official record
Conditions
Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

NCT00335153
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Phase 3 Interventional

Timing of Levodopa Treatment in Parkinson's Disease

NCT00004733
View directory record Official record
Conditions
Parkinson's Disease
Interventions
levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 4:27 PM EDT
Not listed Phase 1 Interventional

Promoting Physical Activity Engagement for People With Early-mid Stage Parkinson's Disease (Engage-PD)

NCT04922190
View directory record Official record
Conditions
Parkinson Disease
Interventions
Physical Activity Coaching
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 10, 2026, 4:27 PM EDT
Not listed Phase 3 Interventional

Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor

NCT00724906
View directory record Official record
Conditions
Parkinsonian Syndromes
Interventions
123 I - ALTROPANE®
Drug
Lead sponsor
Alseres Pharmaceuticals, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hopkinton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 10, 2026, 4:27 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

NCT03457493
View directory record Official record
Conditions
Parkinson Disease
Interventions
DPA-714-PET/MRI, 5-year Follow-up DPA-714-PET/MRI, DPA-714 Metabolite Analysis
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 10, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Physiological Effects of Nutritional Support in Patients With Parkinson's Disease

NCT02445651
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
Intravenous and Oral n-acetyl cysteine, Control group, Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 10, 2026, 4:27 PM EDT